Cancer risk estimates for BCRA1 mutation carriers identified in a risk evaluation program

Journal of the National Cancer Institute

Volumn 94, Issue 18, 2002, Pages 1365-1372

  Brose, Marcia S ^a   Rebbeck, Timothy R ^b   Calzone, Kathleen A ^a   Stopfer, Jill E ^a   Nathanson, Katherine L ^a   Weber, Barbara L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CALCULATION; CANCER EPIDEMIOLOGY; CANCER RISK; COLON CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; FAMILY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MALE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH CANCER; STUDENT T TEST; UTERINE TUBE CARCINOMA;

ADULT; AGE FACTORS; AGED; CHROMOSOMES, HUMAN, PAIR 17; EXONS; FEMALE; GENES, BRCA1; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; OVARIAN NEOPLASMS; PEDIGREE; RISK ASSESSMENT;

EID: 0037130889     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. National Center for Biotechnology Information. OMIM™. Online Mendelian Inheritance in Man. Baltimore (MD): Johns Hopkins University. (For BRCA1 [MIM Number: 113705]. [Last accessed: 8/12/02]. Available at: http://www.ncbi.nlm.nih.gov/omim/.
2. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q2l. Science 1990;250:1684-9.
3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
4. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
5. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
6. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
7. Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998;63:45-51.
8. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-7.
9. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000;18: 173-90.
10. Thompson D, Easton D. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:5-12.
11. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al., editors. SEER cancer statistics review, 1973-1999. Bethesda (MD): National Cancer Institute; 2002.
12. Markman M, Zaino R, Fleming P, Barakat R. Carcinoma of the fallopian tube. In Hoskins W, Perez C, Young R, editors. Principles and practice of gynecologic oncology. 2nd ed. Philadelphia (PA): Lippincott-Raven; 1997. p. 1025-38.
13. Perkins C, Kwong S, Morris C, Cohen R, Allen M, Wright WE. Cancer in California 2001. Sacramento CA: California Department of Health Services, Cancer Surveillance Section; December 2000.
14. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
15. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-9.
16. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001; 10:467-73.
17. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumors in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 1999;35:1248-57.
18. Semba S, Yokozaki H, Yasui W, Tahara E. Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer. Int J Oncol 1998;12:1245-51.
19. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;2:1179-83.
20. Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001;80:176-80.
21. Sobol H, Jacquemier J, Bonaiti C, Dauplat J, Birnbaum D, Eisinger F. Fallopian tube cancer as a feature of BRCA1-associated syndromes. Gynecol Oncol 2000;78:263-4.
22. Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000;76:45-50.
23. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995; 11:428-33.
24. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
25. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 1996;382:678-9.
26. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995;57:1284-97.
27. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 1995;273:535-41.
28. Thompson D, Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002;11:329-36.